Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago. These figures ...
Good day, and thank you for standing by. Welcome to the Prime Medicine Wilson Disease KOL Event Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I ...
Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Prime ...
As part of this agreement, Western Flyer Xpress' power units will use Prime's refrigerated trailers, while both companies will remain independent. Prime Inc. recently entered a partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results